Although the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus (SLE) has required at least a positive anti-nuclear antibody (ANA) titer (≥ 1:80), it remains challenging for clinicians to identify patients with SLE. This study ai
PreS1 epitope recognition in newborns after vaccination with the third-generation Sci-B-Vac™ vaccine and their relation to the antibody response to hepa... p pBackground/p pSci-B-Vac is a recombinant, hepatitis B vaccine derived from a mammalian cell line and containing hepatitis B surface...
Factors associated with the antinuclear antibody (ANA) titer of systemic autoimmune rheumatic diseases in ANA-positive patients after treatment: a retrospective study Abstract Antinuclear antibodies (ANAs) are a serological hallmark of systemic autoimmune rheumatic diseases (SARDs); however, few studies hav...
WSSV-infected hemocytes were subjected to ChIP assays with an anti-c-Jun antibody or normal rabbit IgG (as control). Figure 3G showed that the promoter region of IE1 containing the AP-1 binding motif could be visibly detected by semi-quantitative PCR in the anti-c-Jun antibody ChIP sample...
ANA positivity was defined as a titer of ≥1:40, measured by an enzyme-linked immunosorbent assay (ELISA) on at least two occasions. In our practice, ELISA is used for initial screening, with positive results confirmed by HEp-2 cell indirect immunofluorescence (IFA) upon request to determine...
These trials have reduction of acute and late toxicities associated with current aggressive treatment options in mind and can roughly be divided into two categories: de-intensification of chemotherapy by replacement by cetuximab, a chimeric monoclonal antibody against EGFR, and de-intensification of the...